Evaluation of Haemorrhagic Septicaemia Vaccine formulated with Montanide ISA 61 VG, Corona 8-SO-(RB), Double Oil Adjuvant and Alum
- Post by: bpi
- October 22, 2021
- Comments off
Hung Wui Ho. Evaluation of Haemorrhagic Septicaemia Vaccine formulated with Montanide ISA 61 VG, Corona 8-SO-(RB)m Double Oil Adjuvant and Alum. 30th Veterinary Association of Malaysia (VAM) Congress. 19th-20th October, 2018. Hilton Hotel, Petaling Jaya, Malaysia.(Abstract of e-Poster Presentation).
Hung Wui Ho, Abdul Sukor Shaharudin, Rohaiza Yahaya, Nurulaini Raimy, Norliza Abdul Wahab,Megat Abd Rani Megat Osman, Rohayu Mohd Nasir, Lily Rozita Md Hakin
Veterinary Research Institute, Department of Veterinary Services,59, Jalan Sultan Azlan Shah, 31400 Ipoh, Perak, Malaysia
Corresponding author: email@example.com.
Selection of different formulations in vaccines production is important for safe and sound immunological response in animals. In this study, two new vaccine formulations, which consist of Montanide ISA 61 VG and Corona 8-SO-(RB), respectively were incorporated in preparing the haemorrhagic septicaemia (HS) vaccine. These vaccines were compared with the available HS double oil adjuvant vaccine (HSDA) and HS alum-precipitated vaccine (HSAP) in VRI. All the four vaccines were prepared to maintain the same amount of antigen in all four vaccine formulations. The vaccines were evaluated for their colour, pH, droplet size, stability, injectability and also for the cost of production of each vaccine in 1000 dose. Furthermore, efficacy and potency of the vaccines were tested in mice. Forty-eight mice were divided into 4 groups and injected subcutaneously with the Montanide adjuvanted vaccine, Corona vaccine, HSDA, and HSAP, respectively. After day 21 and 28, six mice from each group were challenged with 109 CFU/ml concentration of Pasteurella multocida serotype B, andthe mortality rate was recorded. Results showed that Montanide adjuvanted vaccine is capable of initiating a quick immune response comparable to HSAP and the immunity in mice lasts for the whole experimental period comparable to Corona vaccine and HSDA. Hence, this study recommends Montanide adjuvanted vaccine as a potential candidate for the production of VRI’s HS vaccine.